ERRATUM

Erratum to: Reassessing the risk of natalizumab-associated PML

Joseph R. Berger^{1,2} · Robert J. Fox^{1,2}

Published online: 29 March 2016
© Journal of NeuroVirology, Inc. 2016

Erratum to: J. Neurovirol.
DOI 10.1007/s13365-016-0427-6

There are some errors in the first column of Table 1. The corrected Table 1 follows.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s13365-016-0427-6>.

✉ Joseph R. Berger
joseph.berger@uphs.upenn.edu

- ¹ Multiple Sclerosis Division of the Department of Neurology,
University of Pennsylvania, 3400 Spruce St., 3 W Gates,
Philadelphia, PA 19104, USA
- ² Mellen Center for Multiple Sclerosis Treatment and Research,
Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

Table 1 Contemporary estimates of risks of natalizumab-associated PML

JCV serology	Previous immunosuppressant therapy	Overall risk	Risk up to 24 months of therapy	Risk after 24 months of therapy
Negative	No	~1:7749	~1:45,798	~1:5022
	Yes	~1:2733	~1:16,151	~1:1171
Positive	No	~1:194	~1:1145	~1:126
	Yes	~1:68	~1:404	~1:44
Anti-JCV antibody positive				
Natalizumab exposure	No prior immunosuppressant use		Prior immunosuppressant use	
1– <24 months	<1:1000		2.5/1000	
≥24 months*	8/1000		23/1000	
JCV serology	Previous immunosuppressant therapy	Overall risk	Risk up to 24 months of therapy	Risk after 24 months of therapy
Negative	No	~1:7749	~1:45,798	~1:5022
	Yes	~1:2733	~1:16,151	~1:1171
Positive	No	~1:194	~1:1145	~1:126
	Yes	~1:68	~1:404	~1:44
Anti-JCV antibody positive				
Natalizumab exposure	No prior immunosuppressant use		Prior immunosuppressant use	
1– <24 months	<1:1000		2.5/1000	
≥24 months*	8/1000		23/1000	

* including cases of PML diagnosed up to 114 infusions

Biogen Data on File